Clinical trials: Cancer Progression
Primary Sclerosing Cholangitis (PSC)
Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)
The purpose of this study is to evaluate whether simtuzumab (GS-6624) is effective at preventing the progression of liver fibrosis in adults with primary sclerosing cholangitis (PSC).
- Trial name
- NCT01672853
- Testing
- Simtuzumab
- Where
- 75 sites in United States, Belgium and 8 more
- Volunteers
- 235 people
- Sponsor
- Gilead Sciences
Advanced or Metastatic Solid Tumor
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab…
- Trial name
- NCT06270706
- Testing
- PLN-101095, Pembrolizumab
- Where
- 22 sites in United States, Spain
- Volunteers
- 124 people
- Sponsor
- Pliant Therapeutics, Inc.
Smoldering Multiple Myeloma (SMM)
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
This study is researching an investigational drug called linvoseltamab ("study drug") in participants at high risk of developing Multiple Myeloma (MM), a group commonly labeled as High-Risk Smoldering Multiple Myeloma (HR-SMM).
- Trial name
- NCT05955508
- Testing
- Linvoseltamab
- Where
- 17 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Regeneron Pharmaceuticals
Untreated Chronic Lymphocytic Leukemia
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.
- Trial name
- NCT04075292
- Testing
- Acalabrutinib, Rituximab, Chlorambucil
- Where
- 46 sites in China, Philippines and 3 more
- Volunteers
- 155 people
- Sponsor
- AstraZeneca
HIV, HIV-Infections
The Visceral Adiposity Measurement and Observation Study
The Visceral Adiposity Measurement and Observation Study
- Conditions
- HIV, HIV-Infections, HIV-1-infection, HIV I Infection
- Trial name
- VAMOS (NCT05383456)
- Testing
- Diagnostic Test, HIV Anti-retroviral Background Therapy
- Where
- 8 sites in United States
- Volunteers
- 196 people
- Sponsor
- Theratechnologies
Gastric Cancer
A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer
The purpose of this study is to evaluate progression-free survival in participants with gastric or gastroesophageal junction cancer who have had disease progression following first-line therapy who undergo treatment with…
- Trial name
- NCT01983878
- Testing
- Ramucirumab
- Where
- 11 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Asthma (Diagnosis)
Longitudinal Phenotyping and Endotyping Study in Adult Patients With Mild, Moderate, or Severe Asthma
Background and study aims: The purpose of this research registry is to understand how asthma varies from person to person and monitor changes that may occur over time.
- Trial name
- MAPLE-UK (NCT07189806)
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Hvivo
Rheumatoid Arthritis
Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate
To compare, as a preliminary analysis, the effects of MEDI-522 versus placebo at 6 months on disease activity (ACR20) and progression of structural joint damage.
- Trial name
- NCT00069017
- Testing
- MEDI-522
- Where
- 40 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- MedImmune LLC
Metastatic Breast Cancer
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
STAGE 1: To determine the safety of enobosarm 9 milligram (mg) once daily (QD) used in combination with a CDK 4/6 inhibitor [Verzenio® (abemaciclib) tablets, for oral use, 150 mg twice daily (BID)].
- Trial name
- VERU-024 (NCT05065411)
- Testing
- Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
- Where
- 30 sites in United States
- Volunteers
- 5 people
- Sponsor
- Veru Inc.
Non-Small Cell Lung Cancer, c-MET
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab…
- Trial name
- NCT07155187
- Testing
- Telisotuzumab Adizutecan, Standard of Care, Osimertinib
- Where
- 117 sites in United States, Australia and 18 more
- Volunteers
- 490 people
- Sponsor
- AbbVie
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
This 2 arm study will compare the efficacy and safety of continuation or discontinuation of Herceptin treatment in combination with 2nd line chemotherapy, in patients with HER2 positive metastatic breast cancer whose condition…
- Trial name
- NCT00444587
- Testing
- Second line chemotherapy, trastuzumab [Herceptin]
- Where
- 30 sites in Bulgaria, Estonia and 6 more
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Gastric Cancer, Adenocarcinoma
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.
- Trial name
- NCT00917384
- Testing
- ramucirumab, Best Supportive Care (BSC)
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 355 people
- Sponsor
- Eli Lilly and Company
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma…
- Trial name
- NCT04704934
- Testing
- Trastuzumab deruxtecan, Ramucirumab, Paclitaxel
- Where
- 156 sites in Argentina, Belgium and 22 more
- Volunteers
- 490 people
- Sponsor
- Daiichi Sankyo
Depression, Bipolar Disorder
Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression
The purpose of this study is to determine if a mobile sensing platform can passively and objectively detect the presence of clinically significant mood disorder symptomatology and symptom progression over time.
- Trial name
- NCT02742064
- Testing
- Cogito Companion Mobile Phone Application
- Where
- United States
- Volunteers
- 899 people
- Sponsor
- Cogito Health Inc
Gastrointestinal Stromal Tumor
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
This study will assess time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.
- Trial name
- NCT01110668
- Testing
- Nilotinib
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 2 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
This single arm study will assess the safety and efficacy of a regimen of Avastin plus a taxane, with or without additional chemotherapy, as first-line treatment in patients with locally recurrent or metastatic breast cancer.
- Trial name
- NCT00448591
- Testing
- bevacizumab [Avastin], Taxane-based chemotherapy
- Where
- 457 sites in Argentina, Australia and 34 more
- Volunteers
- 2,296 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)
1) To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) added to standard-of-care therapy in moderate to severe Chronic Kidney Disease (CKD), on time to first occurrence of any event of the triple composite…
- Trial name
- NCT00500682
- Testing
- AST-120
- Where
- 105 sites in United States, Argentina and 10 more
- Volunteers
- 1,020 people
- Sponsor
- Tanabe Pharma Corporation
COVID-19
Single-Blind Study of STAT-205 in Mild COVID-19
This is a randomized, single blind, study. Males and females meeting inclusion criteria who have symptoms of mild COVID-19 and in whom a positive PCR result for SARS-CoV-2 is obtained may be enrolled to the study treatment within…
- Trial name
- NCT04708327
- Testing
- STAT-205
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cytocom, Inc.
Heart Failure, Cardiomyopathies
Multimodal Physiologic State Intelligence Study
The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state…
- Conditions
- Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute
- Trial name
- OMNIPHYS (NCT07814118)
- Testing
- OMNIPHYS Multimodal Ultrasound Imaging System
- Where
- United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health